– USA, CO – Paragon 28, Inc. (NYSE: FNA), a leader in foot and ankle surgical solutions, announced the appointment of Dave Demski to its Board as an independent director, effective immediately, bringing a wealth of global orthopedic expertise, with over two decades of executive leadership experience.
About Dave Demski
Dave Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of significant growth and innovation milestones. Before his tenure as CEO, he served as CFO, COO, and President, of Emerging Technologies. Mr. Demski has significant public company board experience, having served as a member of Globus Medical’s board from its inception through April 2022, and currently serving as a member of the board of directors of Alphatec Spine (NASDAQ: ATEC) since October 2023 and having previously served on the board of Axonics, Inc. from January 2021 until its acquisition by Boston Scientific in November 2024.
“I am honored to join the Board of Directors at Paragon 28 and to contribute to the company’s incredible mission of transforming the foot and ankle market,” says Dave Demski, newly appointed director for Paragon 28. “I look forward to collaborating with the Board and the Company’s leadership team to continue driving innovation and impacting lives of patients suffering from foot and ankle conditions around the world.”
Dave Demski received a B.S. in Business Administration from the University of Michigan and an M.B.A. from Stanford Graduate School of Business.
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches, and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity or flatfoot, Charcot foo,t, and orthobiologics. The company designs products with both the patient and surgeon in mind, to improve outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.
For more information: https://paragon28.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.